Literature DB >> 15554431

Serotonin brain circuits with a focus on hepatic encephalopathy.

Violina Lozeva-Thomas1.   

Abstract

Despite enormous strides in our understanding of human disease, the precise mechanisms of hepatic encephalopathy (HE), a potential long-term complication of liver failure, are still unclear. Brain serotonin, a neurotransmitter with widespread distribution in the CNS, plays a role in the regulation of a wide range of physiological behaviors and functions. In addition, it has been implicated in the pathogenesis of several pathological processes, including HE. This work reviews the relationship between brain serotonergic dysfunction and hepatic encephalopathy in cirrhotic patients and experimental animals. The existing changes in the synthesis, metabolism, storage, and release of neuronal serotonin in HE point to a serotonergic synaptic deficit in this condition. Given the established role of the brain serotonergic system in the regulation of sleep, circadian rhythmicity, and locomotion, selective alterations of this system could be an important part of the neurophysiological background responsible for the behavioral changes in rats with portacaval anastomosis and may contribute to the pathogenesis of HE in cirrhotic patients. The findings that serotoninergic turnover is exquisitely and selectively sensitive to the degree of porto-systemic shunting and hyperammonemia suggest a role for serotonin in early neuropsychiatric symptoms of HE. Pharmacological manipulation of the brain serotonergic system may be beneficial in the prevention and treatment of HE in cirrhotic patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15554431     DOI: 10.1023/b:mebr.0000043985.25055.b3

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  52 in total

Review 1.  Activity of serotonergic neurons in behaving animals.

Authors:  B L Jacobs; C A Fornal
Journal:  Neuropsychopharmacology       Date:  1999-08       Impact factor: 7.853

2.  Effects of chronic porto-caval anastomosis on brain tryptophan, tyrosine and 5-hydroxytryptamine.

Authors:  G Curzon; B D Kantamaneni; J C Fernando; M S Woods; J B Cavanagh
Journal:  J Neurochem       Date:  1975-05       Impact factor: 5.372

3.  Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine.

Authors:  V ERSPAMER; B ASERO
Journal:  Nature       Date:  1952-05-10       Impact factor: 49.962

4.  Altered adaptive behaviour expressed in an open-field paradigm in experimental hepatic encephalopathy.

Authors:  G Apelqvist; B Hindfelt; G Andersson; F Bengtsson
Journal:  Behav Brain Res       Date:  1999-12       Impact factor: 3.332

5.  Correlation of plasma and brain amino acid and putative neurotransmitter alterations during acute hepatic coma in the rat.

Authors:  A M Mans; S J Saunders; R E Kirsch; J F Biebuyck
Journal:  J Neurochem       Date:  1979-02       Impact factor: 5.372

6.  Tryptophan metabolism in liver disease.

Authors:  C Hirayama
Journal:  Clin Chim Acta       Date:  1971-04       Impact factor: 3.786

7.  Portacaval anastomosis: brain and plasma metabolite abnormalities and the effect of nutritional therapy.

Authors:  A M Mans; J F Biebuyck; D W Davis; R A Hawkins
Journal:  J Neurochem       Date:  1984-09       Impact factor: 5.372

8.  Tryptophan and hepatic coma.

Authors:  J Ono; D G Hutson; R S Dombro; J U Levi; A Livingstone; R Zeppa
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

9.  The role of plasma amino acids in hepatic encephalopathy.

Authors:  J E Fischer; J M Funovics; A Aguirre; J H James; J M Keane; R I Wesdorp; N Yoshimura; T Westman
Journal:  Surgery       Date:  1975-09       Impact factor: 3.982

10.  Long-term effects of portacaval anastomosis on the 5-hydroxytryptamine, histamine, and catecholamine neurotransmitter systems in rat brain.

Authors:  V Lozeva; E MacDonald; A Belcheva; M Hippeläinen; H Kosunen; L Tuomisto
Journal:  J Neurochem       Date:  1998-10       Impact factor: 5.372

View more
  7 in total

1.  Polysomnographic sleep aspects in liver cirrhosis: a case control study.

Authors:  Vinicius Vasconcelos Teodoro; Mauricio Augusto Bragagnolo; Ligia Mendonça Lucchesi; Daniel Cavignolli; Marco Túlio de Mello; Mario Kondo; Sergio Tufik
Journal:  World J Gastroenterol       Date:  2013-06-14       Impact factor: 5.742

2.  The high prevalence of restless legs syndrome symptoms in liver disease in an academic-based hepatology practice.

Authors:  Rose A Franco; Ramesh Ashwathnarayan; Arshana Deshpandee; Joshua Knox; Jack Daniel; Daniel Eastwood; Jose Franco; Kia Saeian
Journal:  J Clin Sleep Med       Date:  2008-02-15       Impact factor: 4.062

3.  The effect of different antidepressant drugs on oxidative stress after lipopolysaccharide administration in mice.

Authors:  Omar M E Abdel-Salam; Safaa M Youssef Morsy; Amany A Sleem
Journal:  EXCLI J       Date:  2011-12-08       Impact factor: 4.068

4.  Machine-Learning Prediction of Oral Drug-Induced Liver Injury (DILI) via Multiple Features and Endpoints.

Authors:  Xiaobin Liu; Danhua Zheng; Yi Zhong; Zhaofan Xia; Heng Luo; Zuquan Weng
Journal:  Biomed Res Int       Date:  2020-05-19       Impact factor: 3.411

5.  Restless leg syndrome a common undiagnosed comorbidity of clinical significance in cirrhosis.

Authors:  Akash Rajender; Saumya Mathur; Priyanka Choudhary; Shalini Upadhyay; Gaurav Rajender; Rajat Bhargava; Subhash Nepalia
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019

Review 6.  The Role of Intestinal Bacteria and Gut-Brain Axis in Hepatic Encephalopathy.

Authors:  Zefeng Chen; Jingsheng Ruan; Dinghua Li; Min Wang; Zhiwei Han; Wenxia Qiu; Guobin Wu
Journal:  Front Cell Infect Microbiol       Date:  2021-01-21       Impact factor: 5.293

7.  TCM Formula Xiaoyaosan Decoction Improves Depressive-Like Behaviors in Rats with Type 2 Diabetes.

Authors:  Na Li; Qun Liu; Xiao-Juan Li; Xiao-Hui Bai; Yue-Yun Liu; Hong-Bo Zhao; Zhong-Ye Jin; Yu-Xia Jing; Zhi-Yi Yan; Jia-Xu Chen
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-05       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.